Table 2.
Survival by univariate analysis
| Characteristics (n) | mPFS (95% CI) | HR (95% CI) | p values | mOS (95% CI) | HR (95% CI) | p values |
|---|---|---|---|---|---|---|
| Median age (years) | 0.373 | 0.124 | ||||
| ≥ 68 (15) | 9.0 (3.3–14.7) | 1 (Reference) | 18.0 (9.2–26.8) | 1 (Reference) | ||
| < 68 (13) | 17.0 (9.2–24.8) | 0.71 (0.32–1.56) | NR | 0.44 (0.15–1.30) | ||
| Gender | 0.143 | 0.323 | ||||
| Male (21) | 10.0 (5.5–14.5) | 1 (Reference) | 22.0 (7.5–36.5) | 1 (Reference) | ||
| Female (7) | 19.0 (0.0–39.5) | 0.49 (0.18–1.33) | NR | 0.48 (0.11–2.14) | ||
| ECOG PS | 0.865 | 0.936 | ||||
| 0 (16) | 11.0 (5.1–16.9) | 1 (Reference) | 24.0 (4.7–43.3) | 1 (Reference) | ||
| 1–2 (12) | 10.0 (1.5–18.5) | 1.07 (0.48–2.39) | 22.0 (3.6–40.4) | 1.04 (0.37–2.94) | ||
| Tumor site | 0.750 | 0.655 | ||||
| GEJ (8) | 13.0 (6.1–19.9) | 1 (Reference) | 33.0 (4.1–61.9) | 1 (Reference) | ||
| Stomach (20) | 9.0 (0.2–17.8) | 1.15 (0.48–2.73) | 22.0 (9.6–34.4) | 1.25 (0.41–4.08) | ||
| Differentiation | 0.737 | 0.550 | ||||
| Differentiated type (23) | 11.0 (7.9–14.1) | 1 (Reference) | 24.0 (4.3–43.7) | 1 (Reference) | ||
| Undifferentiated type (5) | 9.0 (2.6–15.4) | 1.20 (0.40–3.58) | 15.0 (10.7–19.3) | 1.48 (0.40–5.48) | ||
| Visceral metastasis | 0.116 | 0.271 | ||||
| Yes (15) | 8.0 (3.3–12.7) | 1 (Reference) | 15.0 (11.5–18.5) | 1 (Reference) | ||
| No (13) | 13.0 (3.6–22.4) | 0.54 (0.24–1.21) | 33.0 (NA) | 0.56 (0.20–1.60) | ||
| Adjuvant chemotherapy | 0.856 | 0.702 | ||||
| Yes (17) | 11.0 (5.6–16.4) | 1 (Reference) | 33.0 (0.6–65.4) | 1 (Reference) | ||
| No (11) | 10.0 (0.0–24.0) | 0.93 (0.42–2.08) | 22.0 (11.2–32.8) | 1.22 (0.44–3.37) | ||
| Platinum-based | ||||||
| Yes (25) | 12.0 (8.3–15.7) | 1 (Reference) | 0.012 | 24.0 (5.1–42.9) | 1 (Reference) | 0.025 |
| No (3) | 4.0 (NA) | 4.69 (1.18–18.65) | 11.0 (7.8–14.2) | 5.64 (1.02–31.38) | ||
| HER2 status | ||||||
| IHC 3+ (26) | 11.0 (6.0–16.0) | 1 (Reference) | 0.283 | 22.0 (9.4–34.6) | 1 (Reference) | 0.273 |
| IHC 2+/FISH positive (2) | 5.0 (NA) | 2.17 (0.49–9.63) | NR | 0.04 (0.0–251.4) | ||
| HER2 heterogeneity | ||||||
| Yes (14) | 6.0 (2.3–9.7) | 1 (Reference) | <0.001 | 14.0 (11.9–16.1) | 1 (Reference) | 0.003 |
| No (14) | 20.0 (17.8–22.2) | 0.11 (0.03–0.41) | NR | 0.18 (0.06–0.61) | ||
| CEA | ||||||
| ≥ 5.0 ng/ml (15) | 6.0 (0.0–12.3) | 1 (Reference) | 0.659 | 22.0 (8.6–35.4) | 1 (Reference) | 0.804 |
| < 5.0 ng/ml (13) | 12.0 (5.0–19.1) | 0.84 (0.38–1.85) | 24.0 (1.2–46.9) | 0.88 (0.32–2.43) | ||
| CA 19-9 | ||||||
| ≥ 37.0 U/ml (13) | 8.0 (2.4––13.6) | 1 (Reference) | 0.627 | 18.0 (9.9–26.1) | 1 (Reference) | 0.641 |
| < 37.0 U/ml (15) | 11.0 (2.2–19.8) | 0.82 (0.37–1.81) | 24.0 (NA) | 0.64 (0.23–1.77) |
GEJ gastroesophageal junction cancer, ECOG PS Eastern Cooperative Oncology Group Performance Status, HR hazard ratio, 95% CI 95% confidential interval, mPFS median progression-free survival, mOS median overall survival, NA not applicable, NR not reached, CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9